Journal
INTERNATIONAL JOURNAL OF STD & AIDS
Volume 32, Issue 10, Pages 978-980Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/09564624211006568
Keywords
Herpes simplex virus; viral disease; antiviral; other
Categories
Ask authors/readers for more resources
Recurrence of aciclovir-resistant HSV infections is common in immunosuppressed patients, with recommended second-line therapeutic agents associated with significant side effects. In this case, compassionate acquisition of the novel helicase-primase inhibitor pritelivir provided both symptomatic and virological control after second-line therapy failed. This represents the first clinical use of pritelivir in the United Kingdom.
Recurrence of mucocutaneous herpes simplex virus (HSV) infections is common in immunosuppressed patients. Thymidine kinase mutations conferring resistance to the antiviral agent aciclovir have been observed in such patients. Recommended second-line therapeutic agents against HSV are associated with significant side effects contributing to disease burden. We present a case of aciclovir-resistant herpes simplex virus 2 (HSV-2) in an immunosuppressed (HIV negative) allogenic peripheral blood stem cell transplant (SCT) recipient which was refractory to second-line therapy. Compassionate acquisition of the novel oral helicase-primase inhibitor pritelivir provided both symptomatic and virological control for the duration of its use. We believe this to be the first clinical use of this therapeutic agent in the United Kingdom
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available